Skip to content

Effects of electroacupuncture on clinical outcomes in patients with asymptomatic hyperuricemia: multicentre, randomised clinical trial

Efficacy and safety of electroacupuncture versus sham electroacupuncture for treatment of asymptomatic hyperuricemia: multicentre, randomised clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051881
Enrollment
Unknown
Registered
2021-10-09
Start date
2021-10-15
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asymptomatic hyperuricemia

Interventions

EA group:Sixteen sessions of electroacupuncture treatment
Sham EA group:Sixteen sessions of sham ectroacupuncture treatment

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Fasting blood uric acid level 420-660 µmol/L (7-11.0 mg/dL) after 1 month of low-purine diet; 3. No previous history of gouty arthritis; 4. Not receiving drug treatment for hyperuricemia/stopping uric acid-lowering drug treatment for >=12 weeks; 5. BMI 18.5-30.0kg/m^2; 6. Be able to understand and be willing to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Taking other drugs that affect uric acid metabolism in the past 12 weeks, such as: thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, compound reserpine, pyrazinamide, nifedipine, propranolol, and benzbromarone; 2. Secondary hyperuricemia, such as: bone marrow and lymphoproliferative diseases, tumor radiotherapy and chemotherapy, liver cirrhosis and drug-induced hyperuricemia; 3. One of the following comorbidities: hypertension, diabetes, stroke, coronary heart disease, severe liver and kidney damage (>=CKD stage 2, or creatinine, urea, glutamate, glutamate, >=2 times the upper limit of clinical normal); 4. Combined with neuropsychological diseases such as anxiety, depression, intellectual disability; 5. Pregnant patienta; 6. Unwilling to accept acupuncture treatment; 7. The compliance of patients participating in the study is poor, and the completion rate of baseline screening data is <=80%.

Design outcomes

Primary

MeasureTime frame
Change from baseline in serum uric level;

Secondary

MeasureTime frame
Percentage of patients with serum uric acid <=360 µmol/l (6.0 mg/dL);Percentage of patients with serum uric acid <=420 µmol/l (7.0 mg/dL);Rate of gout flares requiring treatment;Change from baseline in weight and BMI;

Countries

China

Contacts

Public ContactTu Shenghao

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

527679774@qq.com+86 13971535353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026